Gastroenterology

S1P Receptor Modulators in Ulcerative Colitis: A Growing Track Record in the Moderate UC Patient’, a BMS promotional symposium that took place at the United European Gastroenterology (UEG) Week 2024. 𝗙𝗼𝗿 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗣𝗿𝗼𝗳𝗲𝘀𝘀𝗶𝗼𝗻𝗮𝗹𝘀 𝗼𝗻𝗹𝘆. 𝗧𝗵𝗶𝘀 𝘀𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 𝘄𝗮𝘀 𝗼𝗿𝗴𝗮𝗻𝗶𝘀𝗲𝗱 𝗮𝗻𝗱 𝗳𝘂𝗻𝗱𝗲𝗱 𝗯𝘆 𝗕𝗿𝗶𝘀𝘁𝗼𝗹 𝗠𝘆𝗲𝗿𝘀 𝗦𝗾𝘂𝗶𝗯𝗯. 𝗕𝗠𝗦 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲𝘀 𝗮𝗻𝗱/𝗼𝗿 𝗽𝗿𝗼𝗱𝘂𝗰𝘁 𝗶𝗻𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝗼𝗻 𝗺𝗮𝘆 𝗯𝗲 𝗱𝗶𝘀𝗰𝘂𝘀𝘀𝗲𝗱. 𝗜𝗠𝗠-𝗚𝗕-𝟮𝟰𝟬𝟬𝟯𝟬𝟯 | 𝗗𝗮𝘁𝗲 𝗼𝗳 𝗣𝗿𝗲𝗽: 𝗔𝗽𝗿𝗶𝗹 𝟮𝟬𝟮𝟱

The new issue of EMJ Gastroenterology is out now, featuring coverage from UEG Week 2024…

The dynamic treatment landscape for eosinophilic oesophagitis (EoE) continues to emphasise symptom relief, often neglecting the underlying…

This BMS-sponsored promotional symposium, presented at the European Crohn’s and Colitis Organisation (ECCO) Congress 2024, presents a thought-provoking view on the latest developments in therapeutic modalities for ulcerative colitis (UC). 𝗙𝗼𝗿 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗣𝗿𝗼𝗳𝗲𝘀𝘀𝗶𝗼𝗻𝗮𝗹𝘀 𝗼𝗻𝗹𝘆. 𝗧𝗵𝗶𝘀 𝘀𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 𝘄𝗮𝘀 𝗼𝗿𝗴𝗮𝗻𝗶𝘀𝗲𝗱 𝗮𝗻𝗱 𝗳𝘂𝗻𝗱𝗲𝗱 𝗯𝘆 𝗕𝗿𝗶𝘀𝘁𝗼𝗹 𝗠𝘆𝗲𝗿𝘀 𝗦𝗾𝘂𝗶𝗯𝗯. 𝗕𝗠𝗦 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲𝘀 𝗮𝗻𝗱/𝗼𝗿 𝗽𝗿𝗼𝗱𝘂𝗰𝘁 𝗶𝗻𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝗼𝗻 𝗺𝗮𝘆 𝗯𝗲 𝗱𝗶𝘀𝗰𝘂𝘀𝘀𝗲𝗱. 𝗜𝗠𝗠-𝗚𝗕-𝟮𝟰𝟬𝟬𝟭𝟭𝟮 | 𝗗𝗮𝘁𝗲 𝗼𝗳 𝗣𝗿𝗲𝗽: 𝗔𝗽𝗿𝗶𝗹 𝟮𝟬𝟮𝟰

Explore the latest updates from ACR Convergence 2023, which discusses the emerging developments and trends within rheumatology and their potential relevance to gastroenterology.

This interdisciplinary expert roundtable discussion which highlights data from the American College of Rheumatology (ACR) 2023…

This webinar explores the ATLANTIS trial, a randomised controlled trial investigating amitriptyline as second-line treatment for irritable…

These BMS-sponsored promotional symposia, presented at the European Crohn’s and Colitis Organisation (ECCO) Congress 2023, highlight multidisciplinary perspectives in ulcerative colitis (UC). Current challenges faced in the management of moderate-to-severe UC, and the role of advanced therapies in UC are discussed by both gastroenterologists and IBD specialist nurses. 𝗙𝗼𝗿 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗣𝗿𝗼𝗳𝗲𝘀𝘀𝗶𝗼𝗻𝗮𝗹𝘀 𝗼𝗻𝗹𝘆. 𝗧𝗵𝗲𝘀𝗲 𝘀𝘆𝗺𝗽𝗼𝘀𝗶𝗮 𝘄𝗲𝗿𝗲 𝗼𝗿𝗴𝗮𝗻𝗶𝘀𝗲𝗱 𝗮𝗻𝗱 𝗳𝘂𝗻𝗱𝗲𝗱 𝗯𝘆 𝗕𝗿𝗶𝘀𝘁𝗼𝗹 𝗠𝘆𝗲𝗿𝘀 𝗦𝗾𝘂𝗶𝗯𝗯. 𝗕𝗠𝗦 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲𝘀 𝗮𝗻𝗱/𝗼𝗿 𝗽𝗿𝗼𝗱𝘂𝗰𝘁 𝗶𝗻𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝗼𝗻 𝗺𝗮𝘆 𝗯𝗲 𝗱𝗶𝘀𝗰𝘂𝘀𝘀𝗲𝗱. 𝗜𝗠𝗠-𝗚𝗕-𝟮𝟯𝟬𝟬𝟯𝟴𝟳 𝗢𝗰𝘁 𝟮𝟯.

Explore the latest insights from EULAR 2023, which discusses the latest developments and research findings on treatment…

Explore the most recent updates from ECCO 2023, which considers the latest insights for IBD management with this expert interdisciplinary…

Explore the latest updates from ACR 2022, which discusses the emerging developments and real-world practices within rheumatology and their…

Explore the latest insights from ECCO 2022, which discusses the latest updates and emerging developments in the treatments of irritable bowel disease (IBD) and rheumatic diseases.

Join our panel of experts in the field of biologics for this CME-accredited webinar where they provide up-to-date knowledge of the…

Join our panel of experts in gastroenterology and inflammatory bowel disease (IBD) for this CME-accredited two-part webinar series on Janus kinase (JAK) inhibitors and their application in clinical practice for IBD considering the recent European Medical Agency (EMA) and U.S. Food and Drug Administration (FDA) recommendations.

The interdisciplinary expert roundtable discussion covers ECCO 2023, new data on anti-TNFs and real-world evidence with biosimilars and more.

Join us for an interdisciplinary expert roundtable discussion to gain a deeper understanding of emerging data from ECCO 2023 and real-world evidence with biosimilars.

Creo Medical is transforming the lives of patients through minimally invasive devices used for therapeutic endoscopic procedures.

A real-life, severe case study of AIP by Professor Ulrich Stoelzel. Video developed and funded by Alnylam Pharmaceuticals

This presidential debate-style discussion explores the topic of biosimilars within rheumatology, dermatology and gastroenterology.

In this webinar Vincent Ho from Western Sydney University, Sydney, Australia covers the pathophysiology of how COVID-19 affects the gut,

Join us for a roundtable discussion to gain a deeper understanding of emerging data from ECCO 2022 and real-world evidence with biosimilars.

Professors Tacke and Cassiman will share their clinical experience of a disease often misdiagnosed or with delayed diagnosis. 

This webinar explores the longstanding relationship between therapeutic drug monitoring (TDM) and inflammatory bowel disease (IBD)

“The Illusion of Remission,” presented at the 15th congress of the European Crohn’s and Colitis Organisation (ECCO) in Vienna, Austria, included…

Dr Jonathan Sackier sat down with Prof Steve Wexner, organiser of the highly successful 2020 International Colorectal DIsease Symposium in Jerusalem…

We spoke to Prof Alberto Arezzo (UEG Scientific Committee Member) at UEG Week 2019, Barcelona, Spain, where he discussed developments in surgical…

We sat down with Prof Abe Fingerhut at the ICDS to discuss his long and illustrious career in colorectal surgery.

Dr Jonathan Sackier sat down with Dr Miklosh Bala to discuss, among other things, trauma surgery in the Israeli capital of Jerusalem.

We spoke to Prof Janneke van der Woude (UEG General Gastroenterology Representative) at UEG Week 2019…

We spoke to Prof Paul Fockens (UEG President) at UEG Week 2019, Barcelona, Spain…

Speaking to us at the 2020 Israel International Colorectal Disease Symposium, Dr Ron Landmann, Chief of Division of Colorectal Surgery/Surgical Oncology…

Speaking to us in the lead-up to the 2020 Israel International Colorectal Disease Symposium, Prof Manish Chand…

Spencer Gore, CEO of EMG-Health, speaks to Professor Jonathan Sackier at the International Colorectal Disease Symposium in Israel about EMG-Health…

An interview with Dr Frank Behrens, Medical Director of the Centre of Innovative Diagnostics and Therapeutics Rheumatology/Immunology Goethe-University…

In this interactive symposium, presented at the 14th Congress of ECCO in Copenhagen, Denmark, on 8th March 2019, the faculty shared key insights into…

Don’t miss out on this year’s UEG Week annual congress, with our quick-look into the Austria Center Vienna venue in Vienna, Austria.

A presentation summarising the design and results from the CALM study, which compared the tight control approach with symptom-driven care in patients…

A presentation summarising the clinical benefits of the treat to target approach in inflammatory bowel disease, particularly reflecting on the changes in…

A symposium highlighting the importance of early diagnosis, assessing prognostic factors, and treating to target in patients with inflammatory…